Proteostasis Therapeutics (PTI) Receiving Somewhat Negative News Coverage, Analysis Finds

Share on StockTwits

News stories about Proteostasis Therapeutics (NASDAQ:PTI) have trended somewhat negative on Thursday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Proteostasis Therapeutics earned a coverage optimism score of -0.13 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.8723670872299 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Proteostasis Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 1st. Royal Bank of Canada cut Proteostasis Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $11.00 to $5.00 in a report on Thursday, June 7th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $12.25.

NASDAQ PTI traded down $0.21 during trading on Thursday, hitting $2.47. The stock had a trading volume of 146,400 shares, compared to its average volume of 1,128,774. The stock has a market capitalization of $98.71 million, a price-to-earnings ratio of -1.06 and a beta of 3.86. Proteostasis Therapeutics has a 12 month low of $1.41 and a 12 month high of $8.61.

Proteostasis Therapeutics (NASDAQ:PTI) last released its earnings results on Wednesday, August 8th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.04). Proteostasis Therapeutics had a negative net margin of 1,087.27% and a negative return on equity of 96.42%. sell-side analysts forecast that Proteostasis Therapeutics will post -2.01 earnings per share for the current fiscal year.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.

See Also: Book Value Per Share in Stock Trading

Insider Buying and Selling by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply